Borús Delfina Lucía, Zadra Giorgia, Minsky Daniel, Costa María Lucía, Córsico Betina, Storch Judith, Scaglia Natalia
Instituto de Investigaciones Bioquímicas de la Plata (INIBIOLP), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Universidad Nacional de La Plata (UNLP), Facultad de Ciencias Médicas, La Plata, Buenos Aires, Argentina.
Institute of Molecular Genetics, National Research Council (CNR-IGM), Pavia, Italy.
Biochim Biophys Acta Mol Cell Biol Lipids. 2025 Jul 8;1870(7):159661. doi: 10.1016/j.bbalip.2025.159661.
Lipid metabolism reprogramming is a well-established hallmark of many cancer types, including colorectal cancer (CRC). Nevertheless, a clear understanding on how fatty acid (FA) metabolism is fine-tuned during CRC development and progression is still missing. Given that CRC is the second leading cause of cancer-related death, addressing these critical aspects may provide the rationale for new therapeutic approaches and early biomarker identification. Fatty acid binding protein 1 (FABP1) is a small protein that binds FA and other lipophilic compounds, acting as a lipid transporter in the intestine. Little is currently known about the function of FABP1 in CRC. Here we show that the knockdown of FABP1 in CRC cells impairs de novo FA and cholesterol synthesis, specifically, via altering the transcriptional regulation of lipid metabolism genes. FABP1 depletion suppresses the expression of FA and cholesterol synthesis-associated genes while promoting that of FA oxidation genes and mitochondrial oxidative pathways. The latter is associated with increased oxygen consumption rate and activation of the energy sensor 5' AMP-activated kinase (AMPK). Taken together, our results show that FABP1 orchestrates the balance between FA synthesis and oxidation, most likely to prevent the cytotoxic effects of circulating unbound free fatty acids. Thus, targeting FABP1 function may represent a potential therapeutic strategy in advanced CRC.
脂质代谢重编程是包括结直肠癌(CRC)在内的多种癌症类型公认的一个特征。然而,目前仍不清楚在CRC发生和发展过程中脂肪酸(FA)代谢是如何被精细调节的。鉴于CRC是癌症相关死亡的第二大主要原因,解决这些关键问题可能为新的治疗方法和早期生物标志物的识别提供理论依据。脂肪酸结合蛋白1(FABP1)是一种能结合FA和其他亲脂性化合物的小蛋白,在肠道中作为脂质转运体发挥作用。目前对FABP1在CRC中的功能了解甚少。在此我们表明,CRC细胞中FABP1的敲低会损害从头合成FA和胆固醇,具体而言,是通过改变脂质代谢基因的转录调控来实现的。FABP1的缺失会抑制FA和胆固醇合成相关基因的表达,同时促进FA氧化基因和线粒体氧化途径相关基因的表达。后者与耗氧率增加和能量传感器5' AMP活化蛋白激酶(AMPK)的激活有关。综上所述,我们的结果表明FABP1协调了FA合成与氧化之间的平衡,很可能是为了防止循环中未结合的游离脂肪酸的细胞毒性作用。因此,靶向FABP1的功能可能代表了晚期CRC的一种潜在治疗策略。